What should be the primary target of "treat to target" in psoriatic arthritis?

What should be the primary target of "treat to target" in psoriatic arthritis?

<h4>Background</h4> <p>Treat to Target in psoriatic arthritis (PsA) recommendations have stated that the target should be remission or inactive disease. Potential definitions include Very Low Disease Activity (VLDA), PsA Disease Activity Score (PASDAS) near remission, Disease Act...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Coates, LC, Lubrano, E, Perrotta, FM, Emery, P, Conaghan, PG, Helliwell, PS
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Journal of Rheumatology 2018

Παρόμοια τεκμήρια

What should be the primary target of ‘treat to target’ in PsA?
ανά: Coates, L, κ.ά.
Έκδοση: (2018)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
ανά: Coates, L, κ.ά.
Έκδοση: (2022)

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
ανά: Coates, L, κ.ά.
Έκδοση: (2019)

Sustained very low disease activity and remission in psoriatic arthritis patients
ανά: Lubrano, E, κ.ά.
Έκδοση: (2019)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
ανά: Lubrano E, κ.ά.
Έκδοση: (2016-10-01)

New approved drugs for psoriatic arthritis
ανά: F.M. Perrotta, κ.ά.
Έκδοση: (2016-09-01)

Precision medicine in psoriatic arthritis: how should we select targeted therapies?
ανά: Al-Mossawi, H, κ.ά.
Έκδοση: (2019)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
ανά: Ennio Lubrano, κ.ά.
Έκδοση: (2019-08-01)

How should we define disease and outcomes in axial psoriatic arthritis?
ανά: Coates, LC
Έκδοση: (2021)

Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis
ανά: Ennio Lubrano, κ.ά.
Έκδοση: (2023-07-01)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
ανά: P.S. Helliwell
Έκδοση: (2011-09-01)

The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.
ανά: Coates, L, κ.ά.
Έκδοση: (2017)

Does treat to target or achieving remission improve radiographic outcome in psa?
ανά: Coates, L, κ.ά.
Έκδοση: (2016)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
ανά: Weinstein, SM, κ.ά.
Έκδοση: (2021)

Novel concepts in psoriatic arthritis management: Can we treat to target?
ανά: Tucker, L, κ.ά.
Έκδοση: (2018)

Mixed methods study of clinicians’ perspectives on barriers to implementation of treat to target in psoriatic arthritis
ανά: Dures, E, κ.ά.
Έκδοση: (2020)

Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis
ανά: Ye, W, κ.ά.
Έκδοση: (2021)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
ανά: Gladman, DD, κ.ά.
Έκδοση: (2022)

The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance study
ανά: Helliwell, PS, κ.ά.
Έκδοση: (2023)

Assessment of patient-physician interactions in psoriatic arthritis: national results of the ASSIST Study
ανά: Perrotta, FM, κ.ά.
Έκδοση: (2024)

Measuring physical function in psoriatic arthritis: comparing the Multi-Dimensional Health Assessment Questionnaire to the Health Assessment Questionnaire Disability Index
ανά: Ye, W, κ.ά.
Έκδοση: (2021)

Occult axial involvement in patients with psoriatic arthritis mutilans: a case report
ανά: F.M. Perrotta, κ.ά.
Έκδοση: (2019-07-01)

Current concepts and unmet needs in psoriatic arthritis
ανά: Mahmood, F, κ.ά.
Έκδοση: (2017)

Psoriatic arthritis: prospects for the future
ανά: Hackett, S, κ.ά.
Έκδοση: (2022)

Should methotrexate have any place in the treatment of psoriatic arthritis?
ανά: Ye, W, κ.ά.
Έκδοση: (2019)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
ανά: Helliwell, PS, κ.ά.
Έκδοση: (2021)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
ανά: Coates, L, κ.ά.
Έκδοση: (2016)

Measuring outcomes in psoriatic arthritis
ανά: Ogdie, A, κ.ά.
Έκδοση: (2020)

Outcome measures in psoriatic arthritis: where next?
ανά: Hackett, S, κ.ά.
Έκδοση: (2022)

Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
ανά: Ennio Lubrano, κ.ά.
Έκδοση: (2022-12-01)

Psoriatic arthritis: lessons from imaging studies and implications for therapy
ανά: Mathew, A, κ.ά.
Έκδοση: (2016)

Assessing disease activity in psoriatic arthritis: a literature review
ανά: Tucker, L, κ.ά.
Έκδοση: (2018)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
ανά: Mease, PJ, κ.ά.
Έκδοση: (2020)

Comparing psoriatic arthritis low-field magnetic resonance imaging, ultrasound and clinical outcomes: data from the TICOPA trial
ανά: Helliwell, P, κ.ά.
Έκδοση: (2019)

Cost-effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of a multicenter randomized controlled trial
ανά: O'Dwyer, J, κ.ά.
Έκδοση: (2018)

Remission in psoriatic arthritis—where are we now?
ανά: Coates, L, κ.ά.
Έκδοση: (2017)

Identification of psoriatic arthritis in patients with psoriasis
ανά: Coates, LC, κ.ά.
Έκδοση: (2023)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
ανά: Soriano, ER, κ.ά.
Έκδοση: (2023)

Psoriatic arthritis: imaging techniques
ανά: E. Lubrano, κ.ά.
Έκδοση: (2012-06-01)

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab
ανά: Coates, L, κ.ά.
Έκδοση: (2018)